Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Japan’s Astellas Pharma has delved deeper into the gene therapy sector, picking up U.K. specialist Quethera for around $109 million.
A Yale University team found two potential methods for preventing fat particles from slipping into tissues.
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
The series B round sees more big-name investors give cash to researchers whose earlier work on PARP inhibitor Lynparza put DDR on the map.
The takeover agreement comes one year after Vernalis was left reeling by a second FDA rejection in quick succession.
PARP inhibitors prevent the misplacement of a specific protein that has been implicated in ALS, new research shows.
The FDA has asked Ampio Pharma to conduct another clinical trial for its osteoarthritis med, Ampion, setting back its BLA.
Another gene therapy alliance shows that Sarepta won’t allow an issue with its lead gene therapy candidate to dampen its enthusiasm for the field.
The Novo Holdings-led mezzanine round comes six months after Therachon began testing its FGFR3 ligand trap in healthy volunteers.
The case relates to a failed multiple sclerosis trial that precipitated a 92% drop in the stock price of Australian biotech Innate Immunotherapeutics.
An FDA advisory committee voted in favor of Paratek’s new antibiotic for acute bacterial skin infections and community-acquired bacterial pneumonia.